Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PUR1800

Small molecule · developed by Pulmatrix

Phase 1 Most advanced trial (none active)
PULM Developer
1 Registered trials

What is PUR1800?

PUR1800 is a drug product of RV1162 in bulk powder pre-metered into HPMC capsules for oral inhalation by a passive dry powder inhaler. It is studied in chronic obstructive pulmonary disease (COPD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Respiratory
Developer
Pulmatrix Inc. (PULM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04759807 Phase 1 Chronic Obstructive Pulmonary Disease (COPD) Completed PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Obstructive Pulmonary Disease (COPD)

More from Pulmatrix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PULM page.

Follow PULM, the company behind PUR1800

See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PULM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.